Impact of Patient Blood Management (PBM) at the Schulthess Clinic A Quality Assurance and Quality Control Project in Major Orthopaedic and Spine Surgery
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 16,000
- 主要终点
- Perioperative transfusion rates
研究概览
简要总结
Aim of this study is to analyze the transfusion requirements of allogenic blood products at the Schulthess Clinic for patients that had major orthopedic or major spine surgery between 2019 and 2024 order to identify patients at risk for transfusion. Moreover, impact of transfusion requirements and other measures of PBM on patient outcomes will be assessed. These data are required to further improve PBM at the Schulthess Clinic.
详细描述
At the Schulthess Clinic a significant reduction of RBC's, fresh frozen plasma (FFP) and platelets transfusion could be observed between 2018 and 2022 during the stepwise introduction of PBM for all patients undergoing major orthopedic and spine surgery. RBC, FFP and PT transfusion declined by 76.3%, 73.5% and 99.2% over the 5-year period. Unfortunately however, at the moment no detailed analysis with respect to risk factors for transfusion, specific interventions or outcomes is available. The hypothesis is that the already known reduction of allogenic blood product transfusion at the Schulthess Clinic can be attributed to patients undergoing major primary joint arthroplasties, revision operations and major spine surgery. We assume that patient and procedure related risk factors over time did not significantly change while we expect a major impact of changed transfusion requirements and the stepwise PBM implementation on patient outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 16 Years 至 99 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients undergoing primary joint arthroplasties or revision surgery: CHOP Code: 81.51, 81.52, 81.52, 81.54
- •Patients undergoing major spine surgery: CHOP Code: 7A.6, 7A.7
排除标准
- •Patients who did not sign general informed consent
结局指标
主要结局
Perioperative transfusion rates
时间窗: 2019-2024
Administration of red blood cells, fresh frozen plasma and platelet concentrates (units)
Risk factors for perioperative transfusion Risk factors for perioperative transfusion Risk factorsfor perioperative transfusion
时间窗: 2019-2024
Identification of patient groups with increased transfusion rates
次要结局
- Perioperative rates of coagulation products administered(2019-2024)
- Clinical outcomes(2019-2024)
研究者
Christoph Hofer
Head of Anesthesia, Professor, Principal Investigator
Schulthess Klinik
